bfgf solution Search Results


90
Bachem saline solution bfgf
Saline Solution Bfgf, supplied by Bachem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bfgf+solution/saline+solution+bfgf/pm10396017-50-28-35
Average 90 stars, based on 1 article reviews
saline solution bfgf - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Boehringer Mannheim bfgf stock solution
Bfgf Stock Solution, supplied by Boehringer Mannheim, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bfgf+solution/bfgf+stock+solution/pmc01572791-48-1-22
Average 90 stars, based on 1 article reviews
bfgf stock solution - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Kaken Pharmaceutical aqueous recombinant human bfgf solution
Aqueous Recombinant Human Bfgf Solution, supplied by Kaken Pharmaceutical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bfgf+solution/aqueous+solution+of+human+recombinant+bfgf/pm19914025-51-1-14
Average 90 stars, based on 1 article reviews
aqueous recombinant human bfgf solution - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Kaken Pharmaceutical bfgf solution
Bfgf Solution, supplied by Kaken Pharmaceutical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bfgf+solution/bfgf+solution/pm24909185-33-1-7
Average 90 stars, based on 1 article reviews
bfgf solution - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
STEMCELL Technologies Inc neurocult supplemented with human recombinant egf, human recombinant bfgf and heparin solution
Neurocult Supplemented With Human Recombinant Egf, Human Recombinant Bfgf And Heparin Solution, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bfgf+solution/neurocult+supplemented+with+human+recombinant+egf++human+recombinant+bfgf+and+heparin+solution/pm30922843-257-20-32
Average 90 stars, based on 1 article reviews
neurocult supplemented with human recombinant egf, human recombinant bfgf and heparin solution - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Kaken Pharmaceutical bfgf solution usable for human fibrastv r
Bfgf Solution Usable For Human Fibrastv R, supplied by Kaken Pharmaceutical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bfgf+solution/bfgf+solution+usable+for+human+fibrastv+r/pm19117294-33-7-13
Average 90 stars, based on 1 article reviews
bfgf solution usable for human fibrastv r - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Kaken Pharmaceutical bfgf solution containing 10 g/100 l bfgf
Bfgf Solution Containing 10 G/100 L Bfgf, supplied by Kaken Pharmaceutical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bfgf+solution/bfgf+solution+containing+10+g+100+l+bfgf/pm11668206-54-65-68
Average 90 stars, based on 1 article reviews
bfgf solution containing 10 g/100 l bfgf - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Taitec Corp the bfgf solution
Variations of <t>bFGF</t> concentration with incubation time up to 72 h in the acellular medium supplemented with ( a ) the non-lyophilized (white triangles) or lyophilized (black triangles) <t>F12</t> <t>membrane,</t> or ( b ) 10 ng/mL of free bFGF (average ± SD; n = 3; * p < 0.05).
The Bfgf Solution, supplied by Taitec Corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bfgf+solution/the+bfgf+solution/pmc07866866-42-20-39
Average 90 stars, based on 1 article reviews
the bfgf solution - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Kaken Pharmaceutical bfgf solution 20μl
Variations of <t>bFGF</t> concentration with incubation time up to 72 h in the acellular medium supplemented with ( a ) the non-lyophilized (white triangles) or lyophilized (black triangles) <t>F12</t> <t>membrane,</t> or ( b ) 10 ng/mL of free bFGF (average ± SD; n = 3; * p < 0.05).
Bfgf Solution 20μl, supplied by Kaken Pharmaceutical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bfgf+solution/bfgf+solution+20%CE%BCl/pm16936435-39-25-11
Average 90 stars, based on 1 article reviews
bfgf solution 20μl - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Scios Nova Inc bfgf scios-nova solution (ph 5) in 9% sucrose, sodium citrate and edta
Variations of <t>bFGF</t> concentration with incubation time up to 72 h in the acellular medium supplemented with ( a ) the non-lyophilized (white triangles) or lyophilized (black triangles) <t>F12</t> <t>membrane,</t> or ( b ) 10 ng/mL of free bFGF (average ± SD; n = 3; * p < 0.05).
Bfgf Scios Nova Solution (Ph 5) In 9% Sucrose, Sodium Citrate And Edta, supplied by Scios Nova Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bfgf+solution/bfgf+scios+nova+solution++ph+5++in+9++sucrose++sodium+citrate+and+edta/us07902172-40-13-14
Average 90 stars, based on 1 article reviews
bfgf scios-nova solution (ph 5) in 9% sucrose, sodium citrate and edta - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Kaken Pharmaceutical aqueous solution of human recombinant bfgf with an isoelectric point of 9.6
Variations of <t>bFGF</t> concentration with incubation time up to 72 h in the acellular medium supplemented with ( a ) the non-lyophilized (white triangles) or lyophilized (black triangles) <t>F12</t> <t>membrane,</t> or ( b ) 10 ng/mL of free bFGF (average ± SD; n = 3; * p < 0.05).
Aqueous Solution Of Human Recombinant Bfgf With An Isoelectric Point Of 9.6, supplied by Kaken Pharmaceutical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bfgf+solution/aqueous+solution+of+human+recombinant+bfgf+with+an+isoelectric+point+of+9+6/10__1111_slash_j__1524___475x__2009__00511__x-31-5-18
Average 90 stars, based on 1 article reviews
aqueous solution of human recombinant bfgf with an isoelectric point of 9.6 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

94
Bio-Techne corporation recombinant rat fgf basic/fgf2/bfgf protein, cf
Variations of <t>bFGF</t> concentration with incubation time up to 72 h in the acellular medium supplemented with ( a ) the non-lyophilized (white triangles) or lyophilized (black triangles) <t>F12</t> <t>membrane,</t> or ( b ) 10 ng/mL of free bFGF (average ± SD; n = 3; * p < 0.05).
Recombinant Rat Fgf Basic/Fgf2/Bfgf Protein, Cf, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bfgf+solution/Recombinant+Rat+FGF+basic%2FFGF2%2FbFGF+Protein%2C+CF/bio-techne+corporation___3339-fb-cf
Average 94 stars, based on 1 article reviews
recombinant rat fgf basic/fgf2/bfgf protein, cf - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

Image Search Results


Variations of bFGF concentration with incubation time up to 72 h in the acellular medium supplemented with ( a ) the non-lyophilized (white triangles) or lyophilized (black triangles) F12 membrane, or ( b ) 10 ng/mL of free bFGF (average ± SD; n = 3; * p < 0.05).

Journal: Materials

Article Title: Storable bFGF-Releasing Membrane Allowing Continuous Human iPSC Culture

doi: 10.3390/ma14030651

Figure Lengend Snippet: Variations of bFGF concentration with incubation time up to 72 h in the acellular medium supplemented with ( a ) the non-lyophilized (white triangles) or lyophilized (black triangles) F12 membrane, or ( b ) 10 ng/mL of free bFGF (average ± SD; n = 3; * p < 0.05).

Article Snippet: The bFGF adsorption process was carried out by immersing the plasma-treated membrane (plasma-treated surface down) in 1 mL of the bFGF solution at 25 °C for 24 h under shaking at 200 rpm with a shaking incubator (DWMaxM BR-104P; TAITEC CORPORATION, Koshigaya, Japan).

Techniques: Concentration Assay, Incubation

Variations of bFGF concentration with incubation time up to 72 h in the acellular medium supplemented with the lyophilized F2, F4, F8, and F12 membranes (average ± SD; n = 3).

Journal: Materials

Article Title: Storable bFGF-Releasing Membrane Allowing Continuous Human iPSC Culture

doi: 10.3390/ma14030651

Figure Lengend Snippet: Variations of bFGF concentration with incubation time up to 72 h in the acellular medium supplemented with the lyophilized F2, F4, F8, and F12 membranes (average ± SD; n = 3).

Article Snippet: The bFGF adsorption process was carried out by immersing the plasma-treated membrane (plasma-treated surface down) in 1 mL of the bFGF solution at 25 °C for 24 h under shaking at 200 rpm with a shaking incubator (DWMaxM BR-104P; TAITEC CORPORATION, Koshigaya, Japan).

Techniques: Concentration Assay, Incubation

( a ) Concentrations of bFGF in the culture medium of human iPSCs on Days 1, 2, and 3, in the medium-change-free continuous culture with the lyophilized F4 membrane (F4 group; gray bars) or F12 membrane (F12 group; black bars), or in standard culture using the bFGF-containing medium with daily medium refreshment (control group; white bars) (average + SD; n = 3; * p < 0.05), and ( b ) phase contrast microscopic images of human iPSCs on Days 1 and 3 in the control, F4, and F12 groups.

Journal: Materials

Article Title: Storable bFGF-Releasing Membrane Allowing Continuous Human iPSC Culture

doi: 10.3390/ma14030651

Figure Lengend Snippet: ( a ) Concentrations of bFGF in the culture medium of human iPSCs on Days 1, 2, and 3, in the medium-change-free continuous culture with the lyophilized F4 membrane (F4 group; gray bars) or F12 membrane (F12 group; black bars), or in standard culture using the bFGF-containing medium with daily medium refreshment (control group; white bars) (average + SD; n = 3; * p < 0.05), and ( b ) phase contrast microscopic images of human iPSCs on Days 1 and 3 in the control, F4, and F12 groups.

Article Snippet: The bFGF adsorption process was carried out by immersing the plasma-treated membrane (plasma-treated surface down) in 1 mL of the bFGF solution at 25 °C for 24 h under shaking at 200 rpm with a shaking incubator (DWMaxM BR-104P; TAITEC CORPORATION, Koshigaya, Japan).

Techniques:

Concentrations of bFGF in the culture medium of human iPSCs, on Day 3 in repeated (up to 5 times) cycles of the medium-change-free continuous culture with the lyophilized F4 membrane (F4 group; gray bars) or of standard culture using bFGF-containing medium with daily medium refreshment (control group; white bars) (average + SD; n = 3; * p < 0.05).

Journal: Materials

Article Title: Storable bFGF-Releasing Membrane Allowing Continuous Human iPSC Culture

doi: 10.3390/ma14030651

Figure Lengend Snippet: Concentrations of bFGF in the culture medium of human iPSCs, on Day 3 in repeated (up to 5 times) cycles of the medium-change-free continuous culture with the lyophilized F4 membrane (F4 group; gray bars) or of standard culture using bFGF-containing medium with daily medium refreshment (control group; white bars) (average + SD; n = 3; * p < 0.05).

Article Snippet: The bFGF adsorption process was carried out by immersing the plasma-treated membrane (plasma-treated surface down) in 1 mL of the bFGF solution at 25 °C for 24 h under shaking at 200 rpm with a shaking incubator (DWMaxM BR-104P; TAITEC CORPORATION, Koshigaya, Japan).

Techniques:

Phase contrast (leftmost column) and fluorescence (right 3 columns) microscopic images of human iPSCs after repeated (5 times) cycles of medium-change-free continuous culture with the lyophilized F4 membrane (F4 group; upper 2 rows) or of standard culture using bFGF-containing medium with daily medium refreshment (control group; lower 2 rows). The iPSCs were stained with FITC (green)-conjugated anti-Nanog, anti-Oct 3/4, and rBC2LCN, and their nuclei were counterstained with DAPI (blue). Insets show higher magnification images.

Journal: Materials

Article Title: Storable bFGF-Releasing Membrane Allowing Continuous Human iPSC Culture

doi: 10.3390/ma14030651

Figure Lengend Snippet: Phase contrast (leftmost column) and fluorescence (right 3 columns) microscopic images of human iPSCs after repeated (5 times) cycles of medium-change-free continuous culture with the lyophilized F4 membrane (F4 group; upper 2 rows) or of standard culture using bFGF-containing medium with daily medium refreshment (control group; lower 2 rows). The iPSCs were stained with FITC (green)-conjugated anti-Nanog, anti-Oct 3/4, and rBC2LCN, and their nuclei were counterstained with DAPI (blue). Insets show higher magnification images.

Article Snippet: The bFGF adsorption process was carried out by immersing the plasma-treated membrane (plasma-treated surface down) in 1 mL of the bFGF solution at 25 °C for 24 h under shaking at 200 rpm with a shaking incubator (DWMaxM BR-104P; TAITEC CORPORATION, Koshigaya, Japan).

Techniques: Fluorescence, Staining

Variations of bFGF concentration with incubation time up to 72 h in acellular medium supplemented with the lyophilized and cryopreserved [( a ) 0, ( b ) 1, ( c ) 3 months] F4 membrane (average ± SD; n = 3).

Journal: Materials

Article Title: Storable bFGF-Releasing Membrane Allowing Continuous Human iPSC Culture

doi: 10.3390/ma14030651

Figure Lengend Snippet: Variations of bFGF concentration with incubation time up to 72 h in acellular medium supplemented with the lyophilized and cryopreserved [( a ) 0, ( b ) 1, ( c ) 3 months] F4 membrane (average ± SD; n = 3).

Article Snippet: The bFGF adsorption process was carried out by immersing the plasma-treated membrane (plasma-treated surface down) in 1 mL of the bFGF solution at 25 °C for 24 h under shaking at 200 rpm with a shaking incubator (DWMaxM BR-104P; TAITEC CORPORATION, Koshigaya, Japan).

Techniques: Concentration Assay, Incubation

Concentrations of bFGF in the culture medium of human iPSCs on Days 1, 2, and 3 in medium-change-free continuous culture with the lyophilized and cryopreserved (3 months) F4 membrane (F4 group; gray bars) or in standard culture using bFGF-containing medium with daily medium refreshment (control group; white bars) (average + SD; n = 3; * p < 0.05).

Journal: Materials

Article Title: Storable bFGF-Releasing Membrane Allowing Continuous Human iPSC Culture

doi: 10.3390/ma14030651

Figure Lengend Snippet: Concentrations of bFGF in the culture medium of human iPSCs on Days 1, 2, and 3 in medium-change-free continuous culture with the lyophilized and cryopreserved (3 months) F4 membrane (F4 group; gray bars) or in standard culture using bFGF-containing medium with daily medium refreshment (control group; white bars) (average + SD; n = 3; * p < 0.05).

Article Snippet: The bFGF adsorption process was carried out by immersing the plasma-treated membrane (plasma-treated surface down) in 1 mL of the bFGF solution at 25 °C for 24 h under shaking at 200 rpm with a shaking incubator (DWMaxM BR-104P; TAITEC CORPORATION, Koshigaya, Japan).

Techniques:

( a ) Viability of iPSCs and ( b ) relative number of viable iPSCs on Day 3 in medium-change-free continuous culture with the lyophilized and cryopreserved (3 months) F4 membrane (F4 group) or in standard culture using bFGF-containing medium with daily medium refreshment (control group) (average + SD; n = 3; * p < 0.05).

Journal: Materials

Article Title: Storable bFGF-Releasing Membrane Allowing Continuous Human iPSC Culture

doi: 10.3390/ma14030651

Figure Lengend Snippet: ( a ) Viability of iPSCs and ( b ) relative number of viable iPSCs on Day 3 in medium-change-free continuous culture with the lyophilized and cryopreserved (3 months) F4 membrane (F4 group) or in standard culture using bFGF-containing medium with daily medium refreshment (control group) (average + SD; n = 3; * p < 0.05).

Article Snippet: The bFGF adsorption process was carried out by immersing the plasma-treated membrane (plasma-treated surface down) in 1 mL of the bFGF solution at 25 °C for 24 h under shaking at 200 rpm with a shaking incubator (DWMaxM BR-104P; TAITEC CORPORATION, Koshigaya, Japan).

Techniques:

Phase contrast (leftmost column) and fluorescence (right 3 columns) microscopic images of human iPSCs on Day 3 in medium-change-free continuous culture with the lyophilized and cryopreserved (3 months) F4 membrane (F4 group; upper 2 rows) or in standard culture using bFGF-containing medium with daily medium refreshment (control group; lower 2 rows). The iPSCs were stained with FITC (green)-conjugated anti-Nanog, anti-Oct 3/4, and rBC2LCN, and their nuclei were counterstained with DAPI (blue). Insets show higher magnification images.

Journal: Materials

Article Title: Storable bFGF-Releasing Membrane Allowing Continuous Human iPSC Culture

doi: 10.3390/ma14030651

Figure Lengend Snippet: Phase contrast (leftmost column) and fluorescence (right 3 columns) microscopic images of human iPSCs on Day 3 in medium-change-free continuous culture with the lyophilized and cryopreserved (3 months) F4 membrane (F4 group; upper 2 rows) or in standard culture using bFGF-containing medium with daily medium refreshment (control group; lower 2 rows). The iPSCs were stained with FITC (green)-conjugated anti-Nanog, anti-Oct 3/4, and rBC2LCN, and their nuclei were counterstained with DAPI (blue). Insets show higher magnification images.

Article Snippet: The bFGF adsorption process was carried out by immersing the plasma-treated membrane (plasma-treated surface down) in 1 mL of the bFGF solution at 25 °C for 24 h under shaking at 200 rpm with a shaking incubator (DWMaxM BR-104P; TAITEC CORPORATION, Koshigaya, Japan).

Techniques: Fluorescence, Staining